Detailed answers about ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED, including incorporation, status, business activity, and accounts information.
When was ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED founded?
ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED was officially incorporated on 7 April 2026 and is registered under company number 17140027. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED?
ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED do?
ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED operates in the following sector: 86220 - Specialists medical practice activities. This provides insight into the company's primary business activity and industry focus.
What is ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED's registered address?
The registered office address of ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED is The Old Farmhouse, Ashley Road, Bradford-On-Avon, England, BA15 1RT. This is the official address filed with Companies House for legal and statutory correspondence.
Is ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED financially stable?
Financial accounts for ADVANCED RADIOPHARMACEUTICAL & CLINICAL LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.